Increased serum concentration of circulating soluble receptor for interleukin-2 and its effect as a prognostic indicator in cachectic patients with gastric and colorectal cancer

Oncology

Volumn 56, Issue 1, 1999, Pages 54-58

  Shibata, Masahiko ^a   Takekawa, Motoo ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cachexia; Colorectal cancer; Gastric cancer; Interleukin 2; Soluble interleukin 2 receptor

Indexed keywords

IMMUNOSUPPRESSIVE ACID PROTEIN; INTERLEUKIN 2 RECEPTOR; NEOPTERIN; PREALBUMIN; TRANSFERRIN; TUMOR NECROSIS FACTOR RECEPTOR;

ALBUMIN BLOOD LEVEL; ARTICLE; CACHEXIA; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE COURSE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; STOMACH CANCER; SURVIVAL TIME; TRANSFERRIN BLOOD LEVEL;

CACHEXIA; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, INTERLEUKIN-2; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0032922358     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000011930     Document Type: Article

References (32)

1. Abe Y, Watanabe Y, Kimura S: The role of tumor necrosis factor receptors in cell signaling and the significance of soluble form levels in the serum. Jpn J Surg 1994;24:197-202.
2. Beutler B, Greenwalt D, Humes JD: Identity of tumor necrosis factor and the macrophage-secreted factor cachectin. Nature 1985;316: 552-554.
3. Cerami A, Ikeda Y, Le Trang N: Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: The role of cachectin (tumor necrosis factor). Immunol Lett 1985;11:173-177.
4. Chilosi M, Semenzato G, Cetto A: Soluble interleukin-2 receptors in sera of patients with hairy cell leukemia: Relationship with the effect of recombinant α-interferon therapy on clinical parameters and natural killer in vitro activity. Blood 1987;70:1530-1535.
5. Denz H, Orth B, Weiss G, Gallati H, Herrmann R, Huber P, Wachter H, Fuchs D: Serum soluble tumor necrosis factor receptor 55 increased in patients with haematological neoplasias and is associated with immune activation and weight loss. Eur J Cancer 1993;29:2232-2235.
6. Fuchs D, Hausen A, Reibnegger G, Werner E, Dierich P, Wachter H: Neopterin as a marker for activated cell-mediated immunity: Application in HIV infection. Immunol Today 1988;9: 150-155.
7. Greene WC, Leonard WJ, Depper JM, Nelson DL, Waldmann TA: The human interleukin-2 receptor. Normal and abnormal expression in T cells and in leukemias induced the human T-lymphotropic retroviruses. Ann Intern Med 1986;105:560-565.
8. Hakin AA: Peripheral blood lymphocytes from patients with cancer lack interleukin-2 (IL-2) receptor expression: Isolation of mRNA encoding IL-2R. Cancer Detect Prev 1988;12:59-63.
9. Holter W, Goldman CK, Casabo L, Nelson DL, Green WC, Waldman TA: Expression of functional IL-2 receptor by lipopolysaccharide and interferon-γ stimulated human monocytes. J Immunol 1987;138:2917-2922.
10. Hyltander A, Wamold I, Eden E, Lundholm K: Effect of whole body protein synthesis after institution of intravenous nutrition in cancer and non-cancer patients who lose weight. Eur J Cancer 1991;27:16-21.
11. Kern AK, Norton JA: Cancer cachexia. J Parenter Enter Nutr 1988;12:286-298.
12. Kloster BE, John PA, Miller LE, Rubin LA, Nelson DL, Blair DC, Tomar RH: Soluble interleukin-2 receptors are elevated in patients with AIDS or at risk of developing AIDS. Clin Immunol Immunopathol 1987;45:440-446.
13. Langstein HN, Doherty GM, Fraker DL, Buresh CM, Norton JA: The roles of γ interferon and tumor necrosis factor a in an experimental rat model of cancer cachexia. Cancer Res 1991; 51:2302-2306.
14. Lawson DH, Richmond A, Nixon DW, Rudman D: Metabolic approaches to cancer cachexia. Annu Rev Nutr 1982;2:277-301.
15. Lonnroth C, Moldawer LL, Gelin J, Kindblom L, Sherry B, Lundholm K: Tumor necrosis factor a and interleukin-1 α production in cachexic, tumor bearing mice. Int J Cancer 1990; 46:889-896.
16. Mackween L, Brown M, Ip SH, Rung PC, Yasuda N, Harrington D, Hinuma Y, Weisenburger D, Lai P, Purtilo D: Serum interleukin-2 receptor as a marker for active T cell malignancies. Fed Proc 1986;45:454.
17. Moldawer LL, Georgieff M, Lundholm K: Interleukin-1, tumor necrosis factor α and the pathogenesis of cancer cachexia. Clin Physiol 1987;7:263-274.
18. Nelson DL, Rubin LA, Kurmann CC, Fritz ME, Boutin B: An analysis of the cellular requirements for the production of soluble interleukin-2 receptors in vitro. J Clin Immunol 1986a;6:114-120.
19. Nelson DL: Soluble interleukin-2 receptor analysis in normal individuals and in certain disease states. Fed Proc 1986b;45:377.
20. Norton JA, Peacock JL, Morrison SD: Cancer cachexia. CRC Crit Rev Oncol Hematol 1987; 2:289-296.
21. Oliff A: The role of tumor necrosis factor (cachectin) in cachexia. Cell 1988;54:141-142.
22. Rubin LA, Kurmann CC, Fritz ME, Biddson WE, Boutin B, Yarchan R, Nelson DL: Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro. J Immunol 1985;135:3172-3177.
23. Seckinger P, Issaz S, Dayer JM: Purification and biological characterization of specific tumor necrosis factor α inhibitor. J Biol Chem 1989;264:11966-11973.
24. Sharma S, Saha K, Shinghal RN, Malik GB: Serum soluble interleukin-2 receptor levels in women with breast carcinoma and its correlation with IL-2 receptor expression on blood lymphocytes and lymphocytic infiltration within the tumour. Cancer Immunol Immunother 1991;33:198-202.
25. Smith KA: The interleukin-2 receptor. Annu Rev Cell Biol 1989;5:397-425.
26. Tartaglia LA, Goeddel GV: Two TNF receptors. Immunol Today 1992;13:151-153.
27. Tisdale MJ: Cancer cachexia. Br J Cancer 1991;63:337-342.
28. Tung KSR, Umland E, Matzner P, Nelson K, Schauf V, Rubin I, Wagner D, Scolland D, Vithayasai P, Vithayasai V, Worobec S, Smith T, Suriyanond V: Soluble serum interleukin-2 receptor levels in leprosy patients. Clin Exp Immunol 1987;69:10-15.
29. Van Eys J: Nutrition and cancer: physiological interrelationships. Annu Rev Nutr 1985;5: 435-439.
30. Vibe-Peterson J, Tvede N, Diamant M, Kjerulff AA, Sorecsen HR, Andersen V: Soluble interleukin-2 receptor and soluble CD8 antigen levels in serum from patients with non-resectable lung cancer. Cancer Immunol Immunother 1991;33:121-127.
31. Wachter H, Fuchs D, Hausen A, Reibnegger G, Werener ER: Neopterin as a marker of activation of cellular immunity: Immunologic basis and clinical application. Adv Clin Chem 1989; 27:81-87.
32. Wesdorp RIC, Krause R, Von Meyenfeldt M: Cancer cachexia and its nutritional implications. Br J Surg 1983;70:352-355.